Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
28 Feb 24
8-K
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
8 Jan 24
8-K
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
5 Dec 23
S-3ASR
Automatic shelf registration
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
8 Nov 23
D
$30.00 mm in equity, sold $30.00 mm, 2 investors
16 Oct 23
8-K
Termination of a Material Definitive Agreement
5 Oct 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
8-K
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
28 Sep 23
8-K
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
27 Sep 23
8-K
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
21 Aug 23
8-K
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
15 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
8 Aug 23
8-K
Departure of Directors or Certain Officers
13 Jul 23
8-K
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
27 Jun 23
S-8
Registration of securities for employees
13 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
13 Jun 23
8-K
Entry into a Material Definitive Agreement
12 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
10 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
8-K
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
26 Apr 23
8-K
Entry into a Material Definitive Agreement
24 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
8-K
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease
27 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
1 Mar 23
8-K
Regulation FD Disclosure
22 Feb 23
8-K
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
9 Jan 23
8-K
Entry into a Material Definitive Agreement
28 Dec 22
8-K
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
16 Dec 22
8-K
Corporate OverviewNovember 2022At the Forefront of Therapies for Rare Diseases
16 Nov 22
Latest ownership filings
4
Samantha Prout
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Bradley L Campbell
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Bradley L Campbell
19 Mar 24
4/A
Bradley L Campbell
15 Mar 24
4/A
John F Crowley
15 Mar 24
4/A
David Michael Clark
15 Mar 24
4/A
Jeff Castelli
15 Mar 24
4/A
Ellen Rosenberg
15 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
GLENN SBLENDORIO
11 Mar 24
4
MICHAEL RAAB
6 Mar 24
4
MARGARET G MCGLYNN
6 Mar 24
4
Bradley L Campbell
5 Mar 24
4
John F Crowley
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
John F Crowley
20 Feb 24
4
Bradley L Campbell
20 Feb 24
4
David Michael Clark
20 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
Ellen Rosenberg
8 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
144
Notice of proposed sale of securities
6 Feb 24
4
Bradley L Campbell
5 Feb 24
4
John F Crowley
5 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
John F Crowley
24 Jan 24